Adiponectin (APN) is an anti-inflammatory hormone derived from adipose tissue that attenuates acute lung injury in rodents. In this study, we investigated the association between circulating APN and outcomes among patients with acute respiratory distress syndrome (ARDS).
We performed a retrospective cohort study using data and plasma samples from participants in the multicenter ARDS Network Fluid and Catheter Treatment Trial.
Plasma APN concentrations were measured in 816 (81.6%) trial participants at baseline and in 568 (56.8%) subjects at both baseline and day 7 after enrollment. Clinical factors associated with baseline APN levels in multivariable-adjusted models included sex, body mass index, past medical history of cirrhosis, and central venous pressure (model R2 = 9.7%). We did not observe an association between baseline APN and either severity of illness (APACHE III) or extent of lung injury (Lung Injury Score). Among patients who received right heart catheterization (n = 384), baseline APN was inversely related to mean pulmonary artery pressure (β = −0.015, R2 1.5%, p = 0.02); however, this association did not persist in multivariable models (β = −0.009, R2 0.5%, p = 0.20). Neither baseline APN levels [HR per quartile1.04 (95% CI 0.91–1.18), p = 0.61], nor change in APN level from baseline to day 7 [HR 1.04 (95% CI 0.89–1.23), p = 0.62)] were associated with 60 day mortality in Cox proportional hazards regression models. However, subgroup analysis identified an association between APN and mortality among patients who developed ARDS from extra-pulmonary etiologies [HR per quartile 1.31 (95% CI 1.08–1.57)]. APN levels did not correlate with mortality among patients developing ARDS in association with direct pulmonary injury [HR 0.96 (95% CI 0.83–1.13)], pinteraction = 0.016.
Citation: Walkey AJ, Demissie S, Shah D, Romero F, Puklin L, Summer RS (2014) Plasma Adiponectin, Clinical Factors, and Patient Outcomes during the Acute Respiratory Distress Syndrome. PLoS ONE 9(9): e108561. https://doi.org/10.1371/journal.pone.0108561
Editor: Jörn Karhausen, Duke University Medical Center, United States of America
Received: May 21, 2014; Accepted: August 22, 2014; Published: September 26, 2014
Copyright: © 2014 Walkey et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Data Availability: The authors confirm that, for approved reasons, some access restrictions apply to the data underlying the findings. All data were obtained from the National Institutes of Health, National Heart Lung and Blood Institute, Biologic Specimen and Data Repository Information Coordinating Center (BioLINCC). As part of our Resource Sharing Plan, we have agreed to upload all data to BIOLINCC after manuscript publication. Readers interested in obtaining Open Source data from the Fluid and Catheter Treatment Trial may submit an application to the BioLINCC website [https://biolincc.nhlbi.nih.gov/home/].
Funding: This study was supported by National Institutes of Health, National Heart Lung and Blood Institute R21HL112672 (AJW) and R01HL105490 (RSS) (http://www.nhlbi.nih.gov/). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: The authors have declared that no competing interests exist.
Adiponectin (APN) is a highly abundant circulating hormone with pleotrophic effects upon diverse pulmonary cell types – including alveolar macrophages, epithelium, and vascular endothelium , , . Though principally derived from adipocytes, circulating APN levels are paradoxically increased in lean individuals and decreased in subjects with higher body mass indexes . In the lung, APN has been shown to have important anti-inflammatory and vascular protective actions, prompting pre-clinical studies examining the role of APN in the pathogenesis of pulmonary disorders including acute respiratory distress syndrome (ARDS) –, 
ARDS is an acute, life-threatening lung condition involving immune and endothelial cell activation that develops in association with direct (e.g. pneumonia) and indirect pulmonary (e.g., urosepsis) challenges . Although the role of circulating APN in human ARDS has not yet been investigated, animal studies suggest a causal link between hypoadiponectemia and ARDS pathogenesis. For example, APN-deficient mice have a markedly increased susceptibility to developing acute lung injury (the murine equivalent of ARDS) , , ,  and this susceptibility is attenuated following APN replacement . Further, mice deficient in APN are prone to developing pulmonary vascular abnormalities including elevated pulmonary artery pressures , a hemodynamic alteration associated with increased mortality among patients with ARDS . Together, these pre-clinical findings prompted our current investigation into the relationship of circulating APN to outcomes in ARDS.
Materials and Methods
We used National Heart, Lung and Blood Institute (NHLBI) ARDS Network Fluid and Catheter Treatment Trial (FACTT) Trial ,  research materials obtained from the NHLBI Biologic Specimen and Data Repository Information Coordinating Center (BioLINCC). The ARDS Network is comprised of 42 hospitals across the United States; details regarding protocols of ARDS Network studies can be found at the ARDSNet.org website. The FACTT trial was a 2×2 factorial design, which randomized patients with ARDS to receive either a right heart catheter or a central venous catheter  and either conservative or liberal fluid management , . Patients receiving conservative fluid management had overall fewer days of mechanical ventilation but otherwise outcomes did not differ significantly between groups. For our study, all analyses and procedures were approved by the Boston University School of Medicine, the Thomas Jefferson University School of Medicine Institutional Review Boards and NHLBI BioLINCC.
Covariates and outcomes
Baseline covariates were measured at FACTT enrollment, which was within 48 hours of the development of ARDS. Data obtained from trial participants included demographics (age, race, sex), anthropometrics (body mass index, height, weight), comorbid conditions (HIV/Acquired Immunodeficiency Syndrome, arthritis, chronic pulmonary disease, cirrhosis, dementia, diabetes mellitus, dialysis dependence, alcohol abuse, congestive heart failure, hepatic encephalopathy, hypertension, immunosuppression, leukemia, lymphoma, myocardial infarction, stroke, metastatic solid tumor, peptic ulcer, peripheral vascular disease), vital signs (blood pressure, heart rate, central venous pressure, fluid intake and output, PaO2/FiO2, vasopressor requirement), laboratory values (albumin, bicarbonate, blood urea nitrogen, chloride, creatinine, glucose, hemoglobin, platelets, potassium, sodium, protein and white blood cell count), Murray lung injury score (a composite radiographic appearance, oxygenation, PEEP level and lung compliance) , and baseline Acute Physiology and Chronic Health Evaluation (APACHE) III score . Among patients randomized to receive a right heart catheterization, recordings of pulmonary artery pressures, pulmonary artery occlusion pressure, cardiac index and transpulmonary pressure gradient (mean pulmonary pressure minus pulmonary artery occlusion pressure) were also utilized. Patients were followed for up to 60 days for outcome of ‘death prior to discharge home with unassisted breathing’.
Plasma APN concentration was measured by enzyme-linked immunosorbent assay using a commercially available kit (R&D Systems, Minneapolis, MN) according to company protocol. All plasma samples were diluted 1∶200 in serum diluting buffer prior to assessing APN concentrations.
The distribution of clinical variables among APN quartiles was compared using Kruskal-Wallis testing and Mantel-Haenzel tests, as appropriate. In order to determine clinical factors associated with APN, variables that were nominally associated with APN levels in univariate analyses (p<0.10) were entered into multivariable linear regression with backward selection (p<0.10). Given a priori associations of age with APN levels and clinical outcomes, age was forced into adjusted models that did not include APACHE scores (which are calculated using age). We excluded variables with >15% missing data from inclusion in multivariable models. APN and change in APN were log-transformed and used as dependent variables in multivariable linear regression analyses. We specifically explored the associations between APN and pulmonary hemodynamics, as well as APN and lung injury scores in multivariable models after adjusting for other clinical factors associated with APN. Separate analyses were performed for clinical factors at baseline and for the change in clinical variables from baseline to day 7. We explored the association of APN with 60-day mortality in Cox proportional hazards models using quartiles of APN levels and clinical variables associated with APN as independent variables. We examined the association of APN with 60-day mortality and quartiles of change in APN (among patients surviving to day 7) in a similar manner. Secondary models that included APN and other variables as time-varying covariates in Cox proportional hazards models were also evaluated. Because of the role of APN in attenuating endothelial activation in animal models of acute lung injury , we performed an exploratory subgroup analysis investigating the association between APN and mortality stratifying patients by either “direct” pulmonary injury (eg., pneumonia, aspiration) or “indirect” injury from extra-pulmonary etiologies (eg., urosepsis, trauma, transfusion) . We used Kaplan-Meier survival plots with log-rank tests to visually demonstrate the association between APN and mortality and report 60day mortality rates generated from the Kaplan-Meier survival function. Finally, we examined Spearman rank correlations between APN and log-transformed ventilator-free days, a composite outcome of duration of mechanical ventilation and mortality . In order to examine whether multiple hypothesis testing might better explain significant (at alpha = 0.05) associations between APN and clinical variables, univariate associations between clinical factors and APN levels were examined in a sensitivity analysis using a Bonferonni-adjusted threshold of p = 0.001 (derived from alpha 0.05/50 tests).
Given that a prior study of critically ill patients with respiratory failure demonstrated an odds ratio for 28-day mortality of 1.59 associated for each 5 ug/ml increase in total APN , we estimated a power of 82% with alpha = 0.05 to detect similar association in the current study. All analyses were performed using SAS 9.1 (Cary, NC, USA), with alpha of 0.05.
Of 1000 FACTT trial participants, plasma was available from 827 subjects at baseline, of whom 816 (81.6%) had detectable APN levels, and from 568 (56.8%) subjects at both baseline and day 7 after enrollment. Trial participants were on average 49.8±16 years old, 53% were male, and 64% were white, with 60-day mortality of 26.8% (219/816). Compared to patients from whom plasma was available, the 184 subjects that were not studied had similar distributions of age (p = 0.92), sex (p = 1.0), race (p = 0.39), etiology of ARDS (p = 0.24), and APACHE III score (p = 0.10). Among the 248 patients who provided baseline but not day 7 plasma samples, 149 (60%) remained hospitalized at day 7, 24 (10%) were discharged home prior to day 7, and 75 (30%) died prior to day 7.
Adiponectin and Clinical Factors
Analysis of plasma APN levels showed that median APN levels increased over the course of hospitalization: baseline [7245 pg/ml (IQR 3610–13288)], day 7 [9451 pg/ml (IQR 5038–15576)] and change from baseline to day 7 [1346 pg/ml (IQR −2194–5879), p<0.001]. Demographic and clinical characteristics grouped according to baseline APN quartiles are shown in Table S1 in File S1. Factors associated with baseline APN levels after inclusion in multivariable-adjusted models included sex, body mass index, past medical history of cirrhosis, and central venous pressure (Table 1, N = 666, model R2 = 9.7%). Baseline APN levels were not associated with APACHE III critical illness severity scores, Murray lung injury scores, or measures of oxygenation (PaO2/FiO2 ratio). Factors associated with change in APN level from baseline to day 7 are shown in Table S2 in File S1. In multivariable analysis, only a history of cirrhosis (β = −0.28, R2 = 0.84%, p<0.04) was associated with change in APN from baseline to day 7.
Table 2 demonstrates the association between baseline APN levels and pulmonary hemodynamic variables among 384 patients who were randomized to receive a pulmonary artery catheter. Baseline APN levels were inversely associated with mean pulmonary arterial pressure (β = −0.015, R2 = 1.5%, p = 0.02) but not with other measures of pulmonary vascular hemodynamics such as transpulmonary pressure, pulmonary artery occlusion pressure or cardiac index. After adjusting for age, race, sex, body mass index, and relevant clinical factors (ie., PEEP, cirrhosis, HIV) association between mean pulmonary artery pressure and baseline APN was attenuated (β = −0.009, R2 = 0.5%, p = 0.20).
Adiponectin and Outcomes
When analyzing all subjects, neither baseline APN levels [APN quartile 4: 43% Kaplan-Meier mortality estimate vs. quartile 1: 36% mortality (Figure 1); HR per APN quartile1.04 (95% CI 0.91–1.18), p = 0.61;], change in APN from baseline to day 7 [HR 1.04 (0.89–1.23), p = 0.62)] nor analysis of APN as a time-varying covariate [HR for ln APN 1.13 (0.99–1.30) p = 0.07] were significantly associated with 60 day mortality. Further, we did not identify an association between baseline APN and ventilator-free days (R2 = 0.14%, p = 0.29).
APN Quartile 1: 95–3589 pg/ml; Quartile 2: 3630–7241 pg/ml; Quartile 3: 7248–13212; Quartile 4: 7248–13212.
To further explore the relationship between APN and mortality we stratified patients based on whether the etiology of ARDS came from direct or indirect lung injury. Patients with indirect lung injury [median 5909 pg/ml (IQR 3332–12127)] had significantly lower baseline APN levels than those with direct lung injury [7784 pg/ml (IQR 4122–14274)] p = 0.004. We observed a significant association between baseline APN levels and mortality among patients with indirect etiologies for ARDS [N = 322, APN quartile 4: 56% Kaplan-Meier mortality vs. quartile 1:34% (Figure 2); HR per APN quartile 1.31 (95% CI 1.08–1.57)]. In contrast, we did not identify an association between APN and mortality among patients developing ARDS in association with direct pulmonary injury [N = 494, APN quartile 4:36% Kaplan-Meier mortality vs. quartile 1: 37% (Figure 3); HR per APN quartile 0.96 (95% CI 0.83–1.13)], p interaction = 0.016. Among patients with indirect lung injuries, the association between baseline APN and mortality persisted after adjustment for age, race, sex, and body mass index [HR per APN quartile 1.29 (95% CI 1.05–1.58)], but this was attenuated after further adjusting for APACHE III score, central venous pressure and positive end expiratory pressure [HR per APN quartile 1.18(95% CI 0.94–1.49)]. No significant interaction was seen for the association between change in APN levels from baseline to day 7, mortality and mechanism of lung injury (p interaction = 0.63).
A significant interaction was demonstrated (p = 0.016) for the association between baseline APN levels and mortality based on whether the mechanism of acute respiratory distress syndrome was presumed to be from “direct” pulmonary injury (eg., pneumonia, aspiration) or “indirect” injury from extra-pulmonary etiologies (eg., urosepsis, trauma, transfusion).
We investigated the clinical correlates and outcomes associated with plasma APN levels in more than 800 patients with well-classified ARDS. In addition to confirming previously-described associations between APN with sex and body mass index, we identified a novel correlation between APN levels and central venous pressures. We did not find a relationship between plasma APN levels and severity of illness or lung injury as measured by either the APACHE III score or the Murray Lung Injury score. Moreover, associations between APN and mean pulmonary arterial pressure did not persist after adjusting for demographic and clinical variables. Consistent with prior studies of critically ill patients , , we found that plasma APN levels were higher at late time points in ARDS when compared to the onset of disease. Surprisingly, neither baseline nor dynamic changes in APN levels were associated with mortality among all patients with ARDS in the present study. However, subgroup analysis showed an association between baseline APN levels (but not changes in APN) and mortality in patients who developed ARDS with extra-pulmonary etiologies.
Animal studies have demonstrated that hypoadiponectinemia predisposes to the onset of acute lung injury and increases the severity of disease –, . However, we are unaware of prior studies examining circulating APN levels, clinical factors, and outcomes in human ARDS. Ahasic et al recently showed that an APN gene polymorphism rs2082940 was associated with poor outcomes in ARDS, but circulating APN levels were not measured in this study . In a single center cohort of 175 mechanically ventilated patients of diverse diagnoses (21% with ARDS), we previously showed that higher APN levels at study enrollment were associated with increased mortality . Similarly, in a population of 170 critically ill patients Koch et al. reported that higher plasma APN levels measured early in the course disease were predictive of increased mortality . In our current investigation we did not identify an association between plasma APN and mortality among all patients with ARDS, although we observed a positive correlation among patients with extra-pulmonary etiologies for ARDS. Our subgroup analysis may explain why previous studies have reported a positive association between APN and mortality among critically ill subjects, as extra-pulmonary conditions were more prevalent in the general intensive care unit populations in prior studies , .
The clinical observations that higher APN levels are associated with poor outcomes appear to conflict with experimental findings in rodents, which have consistently shown a relationship between low adiponectin states (ie, knockout mice) and poor outcomes in acute lung injury , , , . However, in pre-clinical rodent studies (e.g. knock-out mice) changes in APN levels occur prior to the onset of disease, whereas in human studies APN levels are examined after disease onset. Thus, we postulate that higher APN levels in patients early after onset of an acute illness may represent a dysregulated immune response. We propose that future studies exploring this hypothesis focus on patients with extrapulmonary etiologies of ARDS, in whom APN-endothelial ,  interactions may be of greater importance.
Our study confirmed prior associations of plasma APN levels with female sex, low body mass index, and cirrhosis , . Additionally, we identified a novel association between plasma APN levels and central venous pressure. Although this observation was unanticipated, results are consistent with findings in other studies showing that APN acts on systemic blood vessels to increase nitric oxide production and decrease vascular tone . We hypothesize that increased nitric oxide production might partly explain why lower central venous pressures were observed in patients with higher APN levels in our study.
This study has a number of strengths and several limitations. The most obvious strengths are that analyses were performed on a large number of samples and that detailed clinical characteristics were available for all subjects enrolled in our study. While a robust database provided us with sufficient power to detect moderate associations between APN and clinical factors, we recognize that more subtle associations might have been missed by our analyses. We also acknowledge that when testing multiple clinical factors to identify associations there is a greater risk of type I errors. However, our results would not have significantly changed with use of p-values corrected for multiple hypothesis tests. In addition, our analysis of the association between patient outcomes and changes in APN levels over time may have been affected by selection bias; patients without APN levels available on day 7 were more likely to have died prior to day 7 than patients available for sample collection. Measurement of daily APN may better demonstrate associations between temporal changes in APN and clinical outcomes in future studies. One other limitation of our study is that only total APN levels were measured in our samples. Since APN is known to circulate in at least three functionally distinct isoforms ,  it is plausible that changes in individual APN isoforms may have more strongly correlated with outcomes in our study. In addition, analyses among subgroups of ARDS etiology were exploratory and should be considered hypothesis-generating. Lastly, as with all observational studies, causal inference for associations between clinical factors and APN levels is limited.
In conclusion, our study fills multiple knowledge gaps regarding the relationship between APN, clinical factors and clinical outcomes in ARDS. Although we did not observe significant associations between plasma APN and mortality in the entire cohort of patients, we identified novel clinical correlates of APN. Our analysis demonstrates an interaction between the mechanism of lung injury and the association of APN with mortality, a finding that is supported by experimental evidence and argues for further clinical investigation examining the role of APN in patients with indirect causes of ARDS.
This manuscript was prepared using ARDS Network FACTT research materials obtained from the National Heart, Lung and Blood Institute's Biologic Specimen and Data Repository Information Coordinating Center and does not necessarily reflect the opinions or views of the ARDSNet, FACTT or the NHLBI. We thank the ARDS Network investigators and the ARDS Network study participants for their contributions to this work.
Conceived and designed the experiments: AJW SD RSS. Performed the experiments: AJW SD DS FR LP RSS. Analyzed the data: AJW SD RSS. Contributed reagents/materials/analysis tools: DS FR LP RSS. Wrote the paper: AJW SD RSS.
- 1. Nigro E, Scudiero O, Sarnataro D, Mazzarella G, Sofia M, et al. (2013) Adiponectin affects lung epithelial A549 cell viability counteracting TNFalpha and IL-1ss toxicity through AdipoR1. Int J Biochem Cell Biol 45: 1145–1153 10.1016/j.biocel.2013.03.003; 10.1016/j.biocel.2013.03.003.
- 2. Xu L, Bao HG, Si YN, Han L, Zhang R, et al. (2013) Effects of adiponectin on acute lung injury in cecal ligation and puncture-induced sepsis rats. J Surg Res 183: 752–759 10.1016/j.jss.2013.01.055; 10.1016/j.jss.2013.01.055.
- 3. Konter JM, Parker JL, Baez E, Li SZ, Ranscht B, et al. (2012) Adiponectin attenuates lipopolysaccharide-induced acute lung injury through suppression of endothelial cell activation. J Immunol 188: 854–863 10.4049/jimmunol.1100426; 10.4049/jimmunol.1100426.
- 4. van Meurs M, Castro P, Shapiro NI, Lu S, Yano M, et al. (2012) Adiponectin diminishes organ-specific microvascular endothelial cell activation associated with sepsis. Shock 37: 392–398 10.1097/SHK.0b013e318248225e; 10.1097/SHK.0b013e318248225e.
- 5. Summer R, Fiack CA, Ikeda Y, Sato K, Dwyer D, et al. (2009) Adiponectin deficiency: A model of pulmonary hypertension associated with pulmonary vascular disease. Am J Physiol Lung Cell Mol Physiol 297: L432–8 10.1152/ajplung.90599.2008.
- 6. Teoh H, Quan A, Bang KW, Wang G, Lovren F, et al. (2008) Adiponectin deficiency promotes endothelial activation and profoundly exacerbates sepsis-related mortality. Am J Physiol Endocrinol Metab 295: E658–64 10.1152/ajpendo.90384.2008.
- 7. Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, et al. (1999) Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 257: 79–83.
- 8. Li S, Bao HG, Han L, Liu L, Wang X (2012) Effects of adiponectin on mortality and its mechanism in a sepsis mouse model. J Invest Surg 25: 214–219 10.3109/08941939.2011.624257; 10.3109/08941939.2011.624257.
- 9. Ware LB, Matthay MA (2000) The acute respiratory distress syndrome. N Engl J Med 342: 1334–1349 10.1056/NEJM200005043421806.
- 10. Bull TM, Clark B, McFann K, Moss M (2010) National Institutes of Health/National Heart, Lung, and Blood Institute ARDS Network (2010) Pulmonary vascular dysfunction is associated with poor outcomes in patients with acute lung injury. Am J Respir Crit Care Med 182: 1123–1128 10.1164/rccm.201002-0250OC.
- 11. Wiedemann HP, Wheeler AP, Bernard GR, Thompson BT, Hayden D, et al. (2006) Comparison of two fluid-management strategies in acute lung injury. N Engl J Med 354: 2564–75 NEJMoa062200 [pii] 10.1056/NEJMoa062200 [doi].
- 12. Wheeler AP, Bernard GR, Thompson BT, Schoenfeld D, Wiedemann HP, et al. (2006) Pulmonary-artery versus central venous catheter to guide treatment of acute lung injury. N Engl J Med 354: 2213–24 NEJMoa061895 [pii] 10.1056/NEJMoa061895 [doi].
- 13. Wiedemann HP (2008) A perspective on the fluids and catheters treatment trial (FACTT). fluid restriction is superior in acute lung injury and ARDS. Cleve Clin J Med 75: 42–48.
- 14. Murray JF, Matthay MA, Luce JM, Flick MR (1988) An expanded definition of the adult respiratory distress syndrome. Am Rev Respir Dis 138: 720–723.
- 15. Knaus WA, Wagner DP, Draper EA, Zimmerman JE, Bergner M, et al. (1991) The APACHE III prognostic system. risk prediction of hospital mortality for critically ill hospitalized adults. Chest 100: 1619–1636.
- 16. Pelosi P, D'Onofrio D, Chiumello D, Paolo S, Chiara G, et al. (2003) Pulmonary and extrapulmonary acute respiratory distress syndrome are different. Eur Respir J Suppl 42: 48s–56s.
- 17. Schoenfeld DA, Bernard GR (2002) ARDS Network (2002) Statistical evaluation of ventilator-free days as an efficacy measure in clinical trials of treatments for acute respiratory distress syndrome. Crit Care Med 30: 1772–1777.
- 18. Walkey AJ, Rice TW, Konter J, Ouchi N, Shibata R, et al. (2010) Plasma adiponectin and mortality in critically ill subjects with acute respiratory failure. Crit Care Med 38: 2329–2334 10.1097/CCM.0b013e3181fa0561; 10.1097/CCM.0b013e3181fa0561.
- 19. Langouche L, Vander Perre S, Frystyk J, Flyvbjerg A, Hansen TK, et al. (2009) Adiponectin, retinol-binding protein 4, and leptin in protracted critical illness of pulmonary origin. Crit Care 13: R112 10.1186/cc7956.
- 20. Ahasic AM, Zhao Y, Su L, Sheu CC, Thompson BT, et al. (2014) Adiponectin gene polymorphisms and acute respiratory distress syndrome susceptibility and mortality. PLoS One 9: e89170 10.1371/journal.pone.0089170; 10.1371/journal.pone.0089170.
- 21. Koch A, Sanson E, Voigt S, Helm A, Trautwein C, et al. (2010) Serum adiponectin upon admission to the intensive care unit may predict mortality in critically ill patients. J Crit Care 10.1016/j.jcrc.2010.07.015.
- 22. Chen H, Montagnani M, Funahashi T, Shimomura I, Quon MJ (2003) Adiponectin stimulates production of nitric oxide in vascular endothelial cells. J Biol Chem 278: 45021–45026 10.1074/jbc.M307878200.
- 23. Kobayashi H, Ouchi N, Kihara S, Walsh K, Kumada M, et al. (2004) Selective suppression of endothelial cell apoptosis by the high molecular weight form of adiponectin. Circ Res 94: e27–31 10.1161/01.RES.0000119921.86460.37.
- 24. Neumeier M, Weigert J, Schaffler A, Wehrwein G, Muller-Ladner U, et al. (2006) Different effects of adiponectin isoforms in human monocytic cells. J Leukoc Biol 79: 803–808 10.1189/jlb.0905521.